Park Avenue Securities LLC Sells 1,126 Shares of Genmab A/S (NASDAQ:GMAB)

Park Avenue Securities LLC lowered its holdings in Genmab A/S (NASDAQ:GMAB) by 7.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,251 shares of the company’s stock after selling 1,126 shares during the quarter. Park Avenue Securities LLC’s holdings in Genmab A/S were worth $426,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewEdge Wealth LLC raised its stake in Genmab A/S by 50.7% during the 4th quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock valued at $3,820,000 after buying an additional 40,382 shares during the last quarter. Harding Loevner LP lifted its holdings in Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after acquiring an additional 85,665 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Genmab A/S by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after acquiring an additional 3,770 shares during the period. Northern Trust Corp grew its stake in shares of Genmab A/S by 83.3% during the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after purchasing an additional 254,042 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in shares of Genmab A/S during the 4th quarter valued at about $1,143,000. 7.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. BTIG Research raised their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Truist Financial lifted their target price on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $49.50.

Genmab A/S Stock Down 1.8 %

Shares of Genmab A/S stock opened at $25.13 on Friday. The company has a market capitalization of $16.62 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 0.93 and a beta of 0.99. The stock’s 50-day simple moving average is $27.96 and its 200-day simple moving average is $29.11. Genmab A/S has a 52 week low of $24.94 and a 52 week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The company had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. On average, equities analysts expect that Genmab A/S will post 1.11 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.